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CARTA AO EDITOR
Hepatitis C virus (HCV) infection is a major public
health problem, with an estimated prevalence of 2-3%
of worldwide population1. Because Tumour Necrosis
Factor (TNF) seems to have an important role in the im-
mune response to HCV infection by inducing apopto-
sis of the infected cells, suppression by TNF inhibitors
may pose a potential threat of excessive viral replication
and worsening of chronic HCV infection2. Although
previous reports have shown that treating HCV in fected
patients with TNFi does not lead to wor sening of he -
patocyte lesion/liver disease, in the short-term, guide-
lines recommend screening for anti-HCV antibodies
before starting a biological agent and making treatment
decisions only after consulting a gastroenterologist3,4.
We report 3 cases of patients with chronic HCV in-
fection and advanced liver disease, treated with a TNFi,
etanercept (ETN), for a period ranging from 4 months
to 4 years, without hepatitis C treatment and, in two of
them, during concomitant therapy with direct-acting
antiviral agents (DAA) and continued afterwards.
Case 1
Male with rheumatoid arthritis (RA) and HCV-com-
pensated cirrhosis, Child-Pugh score 5, initiated ETN
50mg/week, after maintaining high disease activity with
combination of convencional synthe tic disease modi-
fying anti-rheumatic drugs (cDMARD) and systemic
corticoids. He was medicated for almost 4 years with
ETN 50mg/week without HCV therapy and maintained
stable transaminase levels and viral load (Table I). In
2015, he started a 24 week course of sofosbuvir and
daclatasvir with clearance of the virus, sustained 12 and
24 weeks after treatment cessation. During these 24
weeks of concomitant medication there was a good to -
lerance, without adverse events. Three years after HCV
treatment, the patient maintains ETN with good con-
trol of RA and the viral load remains negative.
Case 2
Male with severe polyarticular Psoriatic Arthritis (PsA)
and HCV infection at cirrhotic stage, initiated at 2008,
treatment with ETN 50mg/week, after failure of 
cDMARD and PUVA phototherapy. Over 2 years, wi th -
out HCV therapy, there was no progression of the li ver
disease, maintaining HCV viral load and transa mina ses
levels stable (Table I). This patient deceased in 2010,
following an ischemic stroke, before DAA became
availa ble.
Case 3
Female diagnosed with PsA (peripheral arthritis and
dactylitis) and HCV infection in cirrhosis stage (Table I),
initiated ETN 50mg/week, after failure and intole rance
to cDMARDs. After 4 months on ETN without hepati-
tis C therapy there was no change in transaminase le -
vels and the viral load decreased (Table I). In 2015, she
was treated with a 24 week course of sofosbuvir and da-
clatasvir with clearance of the virus, persistent at 12
and 24 weeks after treatment cessation. As in case1,
concomitant medication with ETN, sofosbuvir and da-
clatasvir was well tolerated, without adverse events,
and the viral load remained negative three years after
the treatment and under ETN.
Although increasing number of clinical reports sup-
port the short-term safety and efficacy of TNFi in pa-
tients with HCV, some uncertainties remain regarding
long-term safety of these agents5,6. The 3 cases repor ted,
with considerable follow-up time, suggests that the risk
of HCV reactivation related to ETN remains low even
without concomitant antiviral therapy. Nevertheless, a
strict collaboration between rheumatologists and gas-
troenterologists/hepatologists, allied to clini cal and la -
boratory monitoring throughout the treatment period
is advised. The new DAA, highly effective and very well
tolerated are, at present date, the standard of care for
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HCV patients. Our results also showed a good tole -
rance and efficacy when used concomitantly with ETN
in patients 1 and 3.
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Table I. DemographIC anD DIsease CharaCTerIsTICs of paTIenTs
Previous Viral Viral load 3 Exposure
Rheumatic HCV HCV load at or 6 months Previous time to
Patient Sex Age disease genotype therapy baseline* after ETN* csDMARDs anti-TNF**
1 Male 49 RA 3 no 5.87 5.18 Cyclosporine 3 years + 
9 months
2 Male 54 PsA 1b no 5.99 4.8 MTX 2 years
3 Female 61 PsA 3 no 6.55 1.66 MTX, Cyclosporine, 4 months
LEF, SSZ
RA, Rheumatoid Arthritis, PsA, Psoriatic Arthritis; HCV, hepatitis C virus; DMARDs, disease-modifying anti-rheumatic drugs; MTX,
methotrexate, LEF, leflunomide, SSZ, sulfasalazine, ETN, Etanercept. Etanercept was used alone in all patients. Patient 1 met the ACR
criteria for RA. *The values are the log10 copies/ml. **Exposure time to anti-TNF without therapy for Hepatitis C.
